301393.SZ
Suzhou Highfine Biotech Co., Ltd.
SZSE · C 制造业 · CN
CNY 54.67
+3.35%Year over year
Reported trailing growth
- Revenue
- +28.9%
- EBITDA
- —
- EBIT
- -12.7%
- EPS
- -18.7%
- Free cash flow
- —
- Operating cash flow
- +20.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +10.4%
- EBITDA
- +4.2%
- EBIT
- -1.1%
- Net income
- -3.9%
- EPS
- -12.6%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026